Investors with the goal of beating the broader market often turn to stock selection. Strategic choices in individual stocks can have a profound impact on your wealth.
In the latest session, Jazz Pharmaceuticals plc (NASDAQ: JAZZ) closed at $110.12 up 7.10% from its previous closing price of $102.82. In other words, the price has increased by $7.10 from its previous closing price. On the day, 2.63 million shares were traded. JAZZ stock price reached its highest trading level at $110.5 during the session, while it also had its lowest trading level at $95.49.
Ratios:
For a deeper understanding of Jazz Pharmaceuticals plc’s stock, let’s take a closer look at its various ratios. It provided that stocks Price–to–Cash (P/C) ratio for the trailing twelve months (TTM) is standing at 2.23 whereas its Price-to-Free Cash Flow (P/FCF) for the term is 4.93. For the most recent quarter (mrq), Quick Ratio is recorded 3.99 and its Current Ratio is at 4.46. In the meantime, Its Debt-to-Equity ratio is 1.51 whereas as Long-Term Debt/Eq ratio is at 1.50.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for the company, UBS on March 07, 2025, Upgraded its rating to Buy and sets its target price to $179 from $145 previously.
Wells Fargo Upgraded its Equal Weight to Overweight on February 13, 2025, whereas the target price for the stock was revised from $130 to $170.
Insider Transactions:
Additionally, insider trades can be beneficial to investors who want to learn what the management thinks about stock prices in the future. A recent insider transaction in this stock occurred on Apr 01 ’25 when COZADD BRUCE C sold 1,500 shares for $123.75 per share. The transaction valued at 185,625 led to the insider holds 440,307 shares of the business.
COZADD BRUCE C bought 2,000 shares of JAZZ for $250,625 on Apr 01 ’25. On Mar 10 ’25, another insider, Iannone Robert, who serves as the EVP, Global Head of R&D & CMO of the company, sold 2,403 shares for $138.41 each. As a result, the insider received 332,605 and left with 79,621 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, JAZZ now has a Market Capitalization of 6687863296 and an Enterprise Value of 9856097280. As of this moment, Jazz’s Price-to-Earnings (P/E) ratio for their current fiscal year is 12.66, and their Forward P/E ratio for the next fiscal year is 4.82. The expected Price-to-Earnings-to-Growth (PEG) calculation for the next 5 years is 2.46. For the stock, the TTM Price-to-Sale (P/S) ratio is 1.64 while its Price-to-Book (P/B) ratio in mrq is 1.63. Its current Enterprise Value per Revenue stands at 2.422 whereas that against EBITDA is 6.477.
Stock Price History:
The Beta on a monthly basis for JAZZ is 0.49, which has changed by -0.02969426 over the last 52 weeks, in comparison to a change of 0.049593568 over the same period for the S&P500. Over the past 52 weeks, JAZZ has reached a high of $148.06, while it has fallen to a 52-week low of $99.06. The 50-Day Moving Average of the stock is -15.96%, while the 200-Day Moving Average is calculated to be -7.17%.
Shares Statistics:
For the past three months, JAZZ has traded an average of 1.01M shares per day and 1635450 over the past ten days. A total of 60.63M shares are outstanding, with a floating share count of 57.97M. Insiders hold about 4.54% of the company’s shares, while institutions hold 97.57% stake in the company. Shares short for JAZZ as of 1741910400 were 4522312 with a Short Ratio of 4.48, compared to 1739491200 on 4531222. Therefore, it implies a Short% of Shares Outstanding of 4522312 and a Short% of Float of 9.91.
Dividends & Splits
Against a Trailing Annual Dividend Yield of 0.0
